Vaccine
http://www.sciencedirect.com/science/journal/0264410X

Volume 29, Issue 42 pp. 7219-7284 (23 September 2011)
The Development of Dengue Vaccines
Edited by Beth-Ann Coller, Alan D.T. Barrett and Stephen J. Thomas

Introduction
Pages 7219-7220
Beth-Ann Coller, Alan D.T. Barrett, Stephen J. Thomas

The pathogenesis of dengue
Pages 7221-7228
Jamie Whitehorn, Cameron P. Simmons

From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
Pages 7229-7241
Bruno Guy, Beatrice Barrere, Claire Malinowski, Melanie Saville, Remy Teyssou, Jean Lang

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine
Pages 7242-7250
Anna P. Durbin, Beth D. Kirkpatrick, Kristen K. Pierce, Alexander C. Schmidt, Stephen S. Whitehead

Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever
Pages 7251-7260
Jorge E. Osorio, Claire Y.-H. Huang, Richard M. Kinney, Dan T. Stinchcomb

Development of dengue DNA vaccines
Pages 7261-7266
Janine R. Danko, Charmagne G. Beckett, Kevin R. Porter

The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease
Pages 7267-7275
Beth-Ann G. Coller, David E. Clements, Andrew J. Bett, Sangeetha L. Sagar, Jan H. Ter Meulen

Next generation dengue vaccines: A review of candidates in preclinical development
Pages 7276-7284
Julia Schmitz, John Roehrig, Alan Barrett, Joachim Hombach